Ostergaard, L;
Vesikari, T;
Absalon, J;
Beeslaar, J;
Ward, BJ;
Senders, S;
Eiden, JJ;
Jansen, KU;
Anderson, AS;
York, LJ;
et al.
Ostergaard, L; Vesikari, T; Absalon, J; Beeslaar, J; Ward, BJ; Senders, S; Eiden, JJ; Jansen, KU; Anderson, AS; York, LJ; Jones, TR; Harris, SL; O'Neill, R; Radley, D; Maansson, R; Prégaldien, J-L; Ginis, J; Staerke, NB; Perez, JL; B1971009 and B1971016 Trial Investigators
(2017)
A Bivalent Meningococcal B Vaccine in Adolescents and Young Adults.
N Engl J Med, 377 (24).
pp. 2349-2362.
ISSN 1533-4406
https://doi.org/10.1056/NEJMoa1614474
SGUL Authors: Heath, Paul Trafford
|
PDF
Published Version
Available under License ["licenses_description_publisher" not defined]. Download (484kB) | Preview |
Abstract
BACKGROUND: MenB-FHbp is a licensed meningococcal B vaccine targeting factor H-binding protein. Two phase 3 studies assessed the safety of the vaccine and its immunogenicity against diverse strains of group B meningococcus. METHODS: We randomly assigned 3596 adolescents (10 to 18 years of age) to receive MenB-FHbp or hepatitis A virus vaccine and saline and assigned 3304 young adults (18 to 25 years of age) to receive MenB-FHbp or saline at baseline, 2 months, and 6 months. Immunogenicity was assessed in serum bactericidal assays that included human complement (hSBAs). We used 14 meningococcal B test strains that expressed vaccine-heterologous factor H-binding proteins representative of meningococcal B epidemiologic diversity; an hSBA titer of at least 1:4 is the accepted correlate of protection. The five primary end points were the proportion of participants who had an increase in their hSBA titer for each of 4 primary strains by a factor of 4 or more and the proportion of those who had an hSBA titer at least as high as the lower limit of quantitation (1:8 or 1:16) for all 4 strains combined after dose 3. We also assessed the hSBA responses to the primary strains after dose 2; hSBA responses to the 10 additional strains after doses 2 and 3 were assessed in a subgroup of participants only. Safety was assessed in participants who received at least one dose. RESULTS: In the modified intention-to-treat population, the percentage of adolescents who had an increase in the hSBA titer by a factor of 4 or more against each primary strain ranged from 56.0 to 85.3% after dose 2 and from 78.8 to 90.2% after dose 3; the percentages of young adults ranged from 54.6 to 85.6% and 78.9 to 89.7%, after doses 2 and 3, respectively. Composite responses after doses 2 and 3 in adolescents were 53.7% and 82.7%, respectively, and those in young adults were 63.3% and 84.5%, respectively. Responses to the 4 primary strains were predictive of responses to the 10 additional strains. Most of those who received MenB-FHbp reported mild or moderate pain at the vaccination site. CONCLUSIONS: MenB-FHbp elicited bactericidal responses against diverse meningococcal B strains after doses 2 and 3 and was associated with more reactions at the injection site than the hepatitis A virus vaccine and saline. (Funded by Pfizer; ClinicalTrials.gov numbers, NCT01830855 and NCT01352845 ).
Statistics
Actions (login required)
![]() |
Edit Item |